1 / 14

Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes

Featured Article :. Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes.

georgia-knox
Télécharger la présentation

Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Featured Article: Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes Claudia Cavelti-Weder, M.D., Andrea Babians-Brunner, M.D., Cornelia Keller, M.D., Marc A. Stahel, M.D., Malaika Kurz-Levin, M.D., Hany Zayed, Ph.D., Alan M. Solinger, M.D., Thomas Mandrup-Poulsen, M.D., Ph.D., Charles A. Dinarello, M.D., Marc Y. Donath, M.D. Diabetes Care Volume 35: 1654-1662 August, 2012

  2. Study Objective • Metabolic activation of the innate immune system governed by interleukin (IL)-1β contributes to β-cell failure in type 2 diabetes • Gevokizumab is a novel, human-engineered monoclonal anti–IL-1β antibody • Study evaluated safety and biological activity of gevokizumab in patients with type 2 diabetes Cavelti-Weder C et al. Diabetes Care 2012;35:1654-1662

  3. Study Design • 98 patients randomly assigned to placebo (17 subjects) or gevokizumab (81 subjects) at increasing doses and dosing schedules • Primary objective of study was to evaluate the safety profile of gevokizumab • Secondary objectives were to assess pharmacokinetics for different dose levels, routes of administration, and regimens and to assess biological activity Cavelti-Weder C et al. Diabetes Care 2012;35:1654-1662

  4. Results • Study drug well tolerated with no serious adverse events • One hypoglycemic event requiring reduction of dosage of concomitant insulin treatment • Clearance of gevokizumab was consistent with that for human IgG2, with a half-life of 22 days • In the combined intermediate-dose group (single doses of 0.03 and 0.1 mg/kg), mean placebo-corrected decrease in A1C was 0.11, 0.44, and 0.85% after 1, 2 (P= 0.017), and 3 (P = 0.049) months, respectively • Also observed enhanced C-peptide secretion, increased insulin sensitivity, and a reduction in C-reactive protein and spontaneous and inducible cytokines Cavelti-Weder C et al. Diabetes Care 2012;35:1654-1662

  5. Cavelti-Weder C et al. Diabetes Care 2012;35:1654-1662

  6. Cavelti-Weder C et al. Diabetes Care 2012;35:1654-1662

  7. Cavelti-Weder C et al. Diabetes Care 2012;35:1654-1662

  8. Cavelti-Weder C et al. Diabetes Care 2012;35:1654-1662

  9. Cavelti-Weder C et al. Diabetes Care 2012;35:1654-1662

  10. Cavelti-Weder C et al. Diabetes Care 2012;35:1654-1662

  11. Cavelti-Weder C et al. Diabetes Care 2012;35:1654-1662

  12. Cavelti-Weder C et al. Diabetes Care 2012;35:1654-1662

  13. Cavelti-Weder C et al. Diabetes Care 2012;35:1654-1662

  14. Conclusions • This novel IL-1β–neutralizing antibody improved glycemia, possibly via restored insulin production and action, and reduced inflammation in patients with type 2 diabetes • This therapeutic agent may be able to be used on a once-every-month or longer schedule Cavelti-Weder C et al. Diabetes Care 2012;35:1654-1662

More Related